Expert System for Automatic Analysis of Data Quality in Clinical Trials

In the framework of the development scheme 'Central Innovation Scheme for Medium-sized Businesses' of the German Federal Ministry for Economics and Technology (BMWI), clinIT AG, based in Freiburg, Germany, has been awarded a six-figure federal grant in cooperation with the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems.

The IT company, clinIT, intends to develop a novel tool for automatic analysis of data quality in all types of clinical studies. Up to now, such analyses had to be carried out individually for each project via the application programming. On the basis of rules, this new tool will formalize this process and make automatic processing accessible.

For the first time now, this innovation will give project and data managers with no specific programming skills the means to measure and control the quality of data and processes over large-volume study libraries/data bases. The data quality is crucial in a clinical trial, in order to be able to reach accurate and reliable conclusions on the safety and efficacy of the test medication. The new development of clinIT and the Freiburg Institute for Informatics represents not only a decisive advance from the perspective of cost-effectiveness, but especially also in terms of the patient's well-being.

For further information, please visit:
http://www.clinit.net

About clinIT AG
Founded in 2001, clinIT AG is a specialist for clinical information technology whose core business is the development and supply of information systems for both data entry and management of clinical trial data as well as providing support for the process flow in clinical studies. The latter involves systems for data capture, patient randomization and disease management. Further services include statistics, data management and medical consulting. For more information, please visit www.clinit.net.

About the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems
The Institute for Informatics was founded in 1995 and belongs to the Faculty of Applied Sciences of the University. The Faculty for Data Bases and Information Systems has special expertise in the sector of rule-based languages, work flow management systems and internet-based technologies, especially information extraction and integration. Current research projects concern also memory systems for the semantic web and the analysis of correspondingly based query languages. For more information, please visit www.informatik.uni-freiburg.de/.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...